In this video Jenny Yu, Chemical and Life Sciences Industry Leader for Marsh is joined by Charles Ringrose, Public Offering Lead for Marsh Specialty.
Together they cover some of the key risks in an IPO and a De-SPAC transaction within the Life Sciences Industry, and how D&O insurance may help mitigate some of the risks. There are a number of financial benefits of an IPO, SPAC merger / De-SPAC, however, this does mean materially changing a company’s risk profile, by adding significant exposure to the personal assets of a company’s Directors and Officers.
This video offers practical advice on these types of risks, and how they can be mitigated from a D&O insurance perspective. Finally considering the 2022 outlook for the Life Sciences sector.